Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography
| Autor: | Dietmar Winkler, Verena Pichler, Thomas Stimpfl, Marie Spies, Mathis Godbersen, Marcus Hacker, Leo Silberbauer, Georg S. Kranz, Jakob Unterholzner, Gregor Gryglewski, Neydher Berroterán-Infante, Johannes Jungwirth, Birgit Reiter, Markus Mitterhauser, Marius Hienert, Siegfried Kasper, G.M. James, Harald Ibeschitz, Rupert Lanzenberger |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male positron emission tomography ketamine Context (language use) Sulfides Pharmacology Serotonergic DASB Young Adult 03 medical and health sciences chemistry.chemical_compound Serotonin Agents 0302 clinical medicine Thalamus Mesencephalon Humans Medicine Pharmacology (medical) Ketamine Regular Research Article Serotonin transporter Serotonin Plasma Membrane Transport Proteins antidepressant Aniline Compounds biology business.industry serotonin transporter Binding potential Antidepressive Agents 030227 psychiatry 3. Good health Neostriatum Psychiatry and Mental health chemistry Positron-Emission Tomography biology.protein Antidepressant Serotonin business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | International Journal of Neuropsychopharmacology |
| ISSN: | 1469-5111 1461-1457 |
| DOI: | 10.1093/ijnp/pyx085 |
| Popis: | Background Comprehensive description of ketamine’s molecular binding profile becomes increasingly pressing as use in real-life patient cohorts widens. Animal studies attribute a significant role in the substance’s antidepressant effects to the serotonergic system. The serotonin transporter is a highly relevant target in this context, because it is central to depressive pathophysiology and treatment. This is, to our knowledge, the first study investigating ketamine’s serotonin transporter binding in vivo in humans. Methods Twelve healthy subjects were assessed twice using [11C]DASB positron emission tomography. A total of 0.50 mg/kg bodyweight ketamine was administered once i.v. prior to the second positron emission tomography scan. Ketamine plasma levels were determined during positron emission tomography. Serotonin transporter nondisplaceable binding potential was computed using a reference region model, and occupancy was calculated for 4 serotonin transporter-rich regions (caudate, putamen, thalamus, midbrain) and a whole-brain region of interest. Results After administration of the routine antidepressant dose, ketamine showed |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|